Hematology/Oncology Pharmacy Association (HOPA)

A psychosocial telephone counseling intervention can be beneficial for cervical cancer survivors

Interprofessional Teams To Improve Oncology Care

By

Andrea S. Blevins Primeau, PhD, MBA

March 31, 2017

Interprofessional practice provides benefits to patients, team members, and the health care system, by working collaboratively to support and assist each other.

Women with diabetes may have an increased risk of being diagnosed with advanced breast cancer.

Nilotinib Associated With Treatment-induced T2DM and Hyperlipidemia

By

Andrea S. Blevins Primeau, PhD, MBA

March 31, 2017

This study suggest that nilotinib is associated with higher rates of treatment-induced T2DM and hyperlipidemia compared with dasatinib.

Fixed-Combination Netupitant + Oral Palonosetron Effective for the Prevention of Chemotherapy-Induce

No Difference in Aprepitant vs Fosaprepitant in CINV

By

Andrea S. Blevins Primeau, PhD, MBA

March 31, 2017

This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.

Dr Barbara Burtness of Yale University’s School of Medicine discusses the relationship between happi

Facing Ethical Dilemmas in Oncology

By

Andrea S. Blevins Primeau, PhD, MBA

March 31, 2017

Oncology clinicians face ethical dilemmas regarding access to care and treatments, palliative and end-of-life care, and treating vulnerable populations in today’s clinical environment.

ASCO states that it supports Congress, the Obama Administration, and multiple federal agencies in th

Four New Drugs Approved for Multiple Myeloma Since 2015

By

Andrea S. Blevins Primeau, PhD, MBA

March 31, 2017

Four new agents were approved for relapsed/refractory multiple myeloma (RRMM) since 2015, providing more options but adding complexity to the treatment of this disease.

Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising d

Lanreotide Effective Regardless of Prior Octreotide in Carcinoid Syndrome

By

Andrea S. Blevins Primeau, PhD, MBA

March 30, 2017

Lanreotide depot is effective among patients with or without previous octreotide treatment for carcinoid syndrome.

Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhi

Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL

By

Jonathan Goodman, MPhil

March 30, 2017

Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.

Selinexor represents a much-needed therapeutic addition to the available agents for the treatment of

Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

By

Andrea S. Blevins Primeau, PhD, MBA

March 30, 2017

Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.

Experts disagree about whether success in clinical trials translates to success in real world treatm

2016 Oncology Drug Approvals Span Multiple Cancers

By

Andrea S. Blevins Primeau, PhD, MBA

March 30, 2017

At the 2017 HOPA Annual Conference, Vivian Park, PharmD, MBA, BCOP, discussed agents approved by the FDA in oncology in 2016.

At the 2016 ASCO Annual Meeting, presenters discussed the current state and future of immune therapy

Oncology Treatment and Care, The Role of Value-based Frameworks

By

Andrea S. Blevins Primeau, PhD, MBA

March 30, 2017

Multiple value frameworks were developed to help providers, institutions, and payers determine the value of cancer treatment.

Next post in HOPA 2017

High tumor expression of ANXA1 could be predictive of trastuzumab resistance in patients with HER-2

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer